Skip to main content

Microbial Manufacturing Platform for Non-Platform Proteins

CASPON® technology streamlines process development, reduces complexity, and enables a smooth transition from research to manufacturing

In the complex universe of biopharmaceutical manufacturing, platform processes for monoclonal antibodies have become a well-established. However, when it comes to microbial-based biopharmaceuticals, the vast array of molecules that can be expressed in microbes leads to a wide range of manufacturing processes, presenting unique challenges.

One promising solution lies in the translation of process development insights from mammalian to microbial technology and vice versa. Concepts that introduce platform-like steps can simplify processes, streamline development and manufacturing, and boost productivity.

The tag-based platform approach is one such concept. It aims to reduce development timelines and costs, streamline process development, and facilitate a smooth transition from research to manufacturing.

At the forefront of bioprocess development, Boehringer Ingelheim's proprietary CASPON® technology stands as a testament to innovative strategies. It addresses the limitations of existing tag-based systems, offering an efficient and cost-effective solution for manufacturing a broad range of microbial-expressed proteins.

The CASPON® technology, which includes the CASPON® tag and enzyme, simplifies process development, enhances protein expression, and ensures high-quality purification.

Want to learn more about how CASPON® technology can revolutionize biopharmaceutical manufacturing? Don't miss out on these two exciting opportunities: 

9/23/2024 // Boston

Connect with us face to face in Boston.

Sign up now for our microbial expert meeting to discuss current challenges in the microbial manufacturing field and learn from practical cases.
Join us and register here